MIRNA QUANTIFICATION IN PATIENTS WITH SEPTIC SHOCK

ConditionSepsis and Septic Shock

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorInsel Gruppe AG, University Hospital Bern

About this trial

Sepsis-induced immunosuppression (SIS) is a common complication in patients with septic shock. Reduced expression of Human leukocyte antigen isotype DR (HLA-DR) on circulating monocytes is a marker for SIS and correlates with risk of secondary infections and mortality. The miRSep study aims to improve the understanding of early microRNA (miRNA) mediated changes in HLA-DR on monocytes in patients with septic shock.

Eligibility criteria

Qualifiers

New onset (<24h) of septic shock diagnosis according to Sepsis-3 definition

(suspected) infection

Vasopressors required to maintain mean arterial pressure ≥65mm Hg (despite adequate fluid resuscitation)

Serum lactate level > 2mmol/L

Disqualifiers

Age < 18 years

Patients known not to speak German or French

Patients with known.

Pre-existing congenital or acquired severe immune deficiency (e.g. severe combined immunodeficiency, HIV infection, AIDS) or

Trial design

Treatments tested in this trial

Not listed

Trial groups

56 Participants

are grouped into 2 trial groups

Sponsors and collaborators

Insel Gruppe AG, University Hospital Bern

Lead sponsor

Source ClinicalTrials.gov